

Medicine: bictegravir/emtricitabine/tenofovir alafenamide (brand name: Biktarvy®) for HIV

Gilead Sciences Ltd

What is bictegravir/emtricitabine/tenofovir alafenamide used for?

Bictegravir/emtricitabine/tenofovir alafenamide is used to treat adults infected with the human immunodeficiency virus type 1 (HIV-1). This virus causes acquired immune deficiency syndrome (AIDS). In some cases, the HIV can become resistant to certain medicines because of changes (mutations) that happen in the genetic material of the virus.

How does bictegravir/emtricitabine/tenofovir alafenamide work?

Bictegravir/emtricitabine/tenofovir alafenamide is a combination of three different active ingredients that block different proteins that are important for HIV-1 multiplying and infecting cells. It is only to be used in patients who have HIV-1 that has no mutations known to cause the virus to be resistant to any of the three components.

What has SMC said?

SMC has accepted bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) for the treatment of adults infected with HIV-1 as described above.



Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration of the evidence and after the company applied a confidential discount to the cost of the medicine, SMC was able to accept it as a possible treatment within NHSScotland.

What does SMC's decision mean for me?

If your healthcare professional thinks that bicitgravir/emtricitabine/tenofovir alafenamide for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland. For further information see: Medicines in Scotland: What's the right treatment for me?
www.healthcareimprovementscotland.org/medicinesbooklet.aspx



More information

The organisations below can provide more information and support for people with HIV and their families. SMC is not responsible for the content of any information provided by external organisations.

Waverley Care



<http://www.waverleycare.org/>



0131 558 1425

HIV Scotland



<http://www.hivscotland.com/>



0131 558 3713

You can find out more about bicitgravir/emtricitabine/tenofovir alafenamide in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

Date advice published: 10 September 2018

SMC No: (SMC2093)